Aisi asked EMA for approval of the anti-epileptic drug Fycompa ® (Verumpanai) for the treatment of children with epilepsy

today, Aishi announced that it has submitted an application to the EuropeanMedicines(http://Authority (EMA) for approval of the use of the anti-epilepticdrug(http://Fycompa ® (Verumpana) for the treatment of children with epilepsythe application is intended to expand Fycompa's indications to cover childrenprior to, Fycompa has been approved for addition treatment for patients 12 years of age and older with partial seizures (accompanied by or non-secondary full-blown seizures) or primary all-round aggressive - seizure sympastAbout Fycompaanti-epilepticnew drug(http://Fycompa by The weisan's wave research laboratory found that is a highly selective, non-competitive AMPA receptor antagonists that can reduce neuronal overexcitement by targeting the glutamate activity on AMPA receptors on the membrane of synapsesFycompa tablets are available for sale once a dayThe drug has been approved in more than 55 countries worldwide and has so far benefited more than 200,000 patientsFycompa was approved to extend the disease to children in the United States in September 2018 and filed the application in Japan in January 2019The studybased on the results of a phase III clinical study (311 studies) and a Phase II clinical study (232 studies) conducted worldwidethe purpose of the above study was to evaluate The treatment of Fycompa for the addition of epilepsy in childrenThe 311 study assessed the safety and tolerance of Fycompa for addition to treatment for children with epilepsy (ages 4 to 12) who had partial seizures or severe dysphyl seizures that were not completely controlled with other drugsStudy 232 assessed pharmacokinetics, efficacy and long-term safety of the addition of TheMolumpanai to treat children with epilepsy (2 to 12 years of age)